The company has multiple biosimilar products on the worldwide market and in development; in 2019, it gained World Health Organization precertification for a trastuzumab biosimilar (Ontruzant).
Samsung Bioepis has won the Biosimilar Initiative of the Year award from the publisher Informa and health care analytics company IQVIA. The award is given in recognition of exceptional leadership in expanding access to biosimilars.
In late 2019, Samsung Bioepis, based in Incheon, Republic of Korea, won World Health Organization (WHO) prequalification for its trastuzumab biosimilar Ontruzant. The WHO designation helps to build worldwide acceptance of the agent and expands access to populations in need of lower-cost medicine. Also in 2019, Samsung Bioepis expanded its biosimilar marketing activities in Asia and Latin America.
In August 2020 the company expanded into the Brazilian biosimilars market, considered one of the fastest growing biosimilars markets among emerging nations.
In the United States, the company launched Ontruzant in April 2020 and has 2 biosimilars approved but not yet marketed: Eticovo (etanercept) and Hadlima (adalimumab). Originator product exclusivity rights are keeping these from market. Samsung Bioepis has 5 drug products approved and marketed in Europe in immunology and oncology.
The Biosimilar Initiative award is given to a company with a biosimilar marketed or approved or under development, actively marketing biosimilars, and working to increase biosimilar use and distribution.
“This award is a testament of the tremendous work that we’ve put toward realizing our vision and commitment to become a globally recognized biopharmaceutical company delivering high quality medicines to the people who need them the most,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis.
Informa, based in London, England, and IQVIA, headquartered in Atlanta, Georgia, sponsor the Global Generics & Biosimilars Awards each year, and this recognition of Samsung Bioepis was part of that. Informa is a publishing company and IQVIA is a data analytics consultant.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.